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AA = arachidonic acid; COX = cyclo-oxygenase; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; LC = long chain; MUFA = monoun-
saturated fatty acid; NSAID = nonsteroidal anti-inflammatory drug; PBB = polybrominated biphenyl; PCB = chlorinated biphenyl; PG = prostaglandin;
PUFA = polyunsaturated fatty acid; RA = rheumatoid arthritis; TNF = tumour necrosis factor; TX = thromboxane.
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Abstract
There is a general belief among doctors, in part grounded in
experience, that patients with arthritis need nonsteroidal anti-
inflammatory drugs (NSAIDs). Implicit in this view is that these
patients require the symptomatic relief provided by inhibiting
synthesis of nociceptive prostaglandin E2, a downstream product
of the enzyme cyclo-oxygenase (COX), which is inhibited by NSAIDs.
However, the concept of ‘safe’ NSAIDs has collapsed following a
multiplicity of observations establishing increased risk for cardio-
vascular events associated with NSAID use, especially but not
uniquely with the new COX-2-selective NSAIDs. This mandates
greater parsimony in the use of these agents. Fish oils contain a
natural inhibitor of COX, reduce reliance on NSAIDs, and reduce
cardiovascular risk through multiple mechanisms. Fish oil thus
warrants consideration as a component of therapy for arthritis,
especially rheumatoid arthritis, in which its symptomatic benefits
are well established. A major barrier to the therapeutic use of fish
oil in inflammatory diseases is ignorance of its mechanism, range of
beneficial effects, safety profile, availability of suitable products,
effective dose, latency of effects and instructions for administration.
This review provides an evidence-based resource for doctors and
patients who may choose to prescribe or take fish oil.
Introduction
Essential dietary constituents are those that cannot be
synthesized endogenously. Vitamins are familiar examples of
essential micronutrients. The dietary essential fatty acids are
polyunsaturated fatty acids (PUFAs) that contain the n6 with
or without the n3 double bond, neither of which can be
synthesized endogenously. The n6 (or ω6) PUFAs contain the
n6 double bond, and the n3 (or ω3) PUFAs have both n6 and
n3 double bonds. (The n or ω notation refers to the position
of the double bond relative to the methyl terminus of the fatty
acid molecule.) In contrast to vitamins, n6 and n3 fatty acids
are macronutrients, and diets in industrialized Western
countries are generally abundant in n6 PUFAs and poor in n3
PUFAs. This is potentially important because the ratios of
these fatty acids in the tissues are determined largely by their
ratios in the diet [1,2].
Dietary sources of n3 and n6 polyunsaturated
fatty acids
In seeking to alter the balance of n3 and n6 PUFAs in the
tissues with therapeutic intent, it is necessary to understand
which foods are rich in these fatty acids. This allows n3-rich
items to be selected and n6-rich items to be avoided. In
addition to fish oils, n3 PUFAs are found in the flesh of all
marine fish, including crustaceans and shellfish. In fish and
fish oils, n3 PUFAs are present as long chain (LC) PUFAs
(i.e. 20 and 22 carbon atoms long [C20 and C22,
respectively]) PUFAs. In certain vegetable oils, notably
flaxseed, perilla and, to a lesser extent, canola oil, n3 PUFAs
are present as the C18 PUFA α-linolenic acid (C18:3n3). In
sunflower, cottonseed, safflower and soy oils, and the
spreads manufactured from them, the main fatty acid is the
n6 C18 PUFA linoleic acid (C18:2n6). Olive oil and canola oil
are rich sources of oleic acid (C18:1n9), which is a
monounsaturated fatty acid (MUFA) containing a single
double bond in the n9 position. Oleic acid can be
endogenously synthesized by humans, and so it is not an
essential fatty acid (Table 1).
Because Western diets are typically low in LC n3 PUFAs,
substantial increases in tissue LC n3 can be achieved by
taking a fish oil supplement without further dietary modifica-
tion [3]. However, choice of spreads that are rich in n3
PUFAs or rich in MUFAs and low in n6 PUFAs allows higher
tissue n3 levels to be reached with a given dose of fish oil
[3,4]. To achieve anti-inflammatory doses of LC n3 PUFAs by
eating fish, a more substantial intake is required than would be
practical for most people. The conversion of C18 n3 PUFAs to
C20 and C22 n3 PUFAs occurs relatively inefficiently in
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humans, and so vegetable sources of dietary n3 PUFAs alone
fail to achieve the tissue levels seen with fish oil [5].
Biochemical rationale
Eicosanoids: cyclo-oxygenase pathway
The pain of arthritis is mediated in part by prostaglandin
(PG)E2 – a nociceptive factor that is synthesized at sites of
inflammation through the inducible isoform of cyclo-
oxygenase (COX), namely COX-2. The COX isozymes,
whether COX-1 or COX-2, are inhibited by nonsteroidal anti-
inflammatory drugs (NSAIDs).
The usual substrate for the COX isozymes is the n6 LC PUFA
arachidonic acid (AA; 20:4n-6). Eicosapentaenoic acid (EPA;
20:5n-3), which is present in fish oil, differs from AA only by
the presence of its n3 bond (Fig. 1).
Being a chemical homologue, EPA is both an inhibitor of AA
metabolism and an alternate substrate for COX. Whereas AA
is converted by COX to the n6 prostaglandin PGH2, EPA is
converted to the n3 homologue PGH3. The latter influences
the synthesis of downstream products of COX in ways not
seen with NSAIDs (Fig. 2). PGH3 is an inhibitor but a poor
substrate of PGE synthase. PGH3 is both inhibitor and
alternate substrate of thromboxane (TX) synthase but the n3
product TXA3 has little biological activity. PGH3 is a poor
inhibitor of PGI synthase and is converted to PGI3, which has
activity similar to that of PGH2. Thus, the net effect of fish oil
is to reduce the production of proinflammatory and anti-
thrombotic eicosanoids (PGE2 and TXA2, respectively) but
not the vascular patency factor prostacyclin (PGI2; Fig. 2) [6].
The effect on PGE2 may explain in part the symptomatic
benefit of fish oil seen in rheumatoid arthritis (RA) [7,8] (see
the section on clinical evidence for the anti-inflammatory
effects of fish oil, below) and the reduced discretionary use of
NSAIDs seen in RA patients taking anti-inflammatory doses of
fish oil [9-11].
The development of selective COX-2 inhibitors for use as
NSAIDs with reduced or no upper gastrointestinal adverse
effects was predicated on the observation that PGE2 at
inflammatory foci was COX-2 derived, whereas gastro-
protective PGE2 was COX-1 derived. This scheme fails to
Table 1
Dietary sources of fatty acids
Foods and ingredients Fatty acids contained in the foods Comments
Fish and/or fish oil Long chain n3 PUFAs such as EPA  EPA and DHA are the beneficial n3 PUFAs
(C20:5n-3) and DHA (C22:6n-3)
Flaxseed and canola oil The shorter chain n3 PUFA ALA  ALA is converted to EPA or DHA after ingestion, but not very efficiently. 
(C18:3n-3). However, it can still provide a useful dietary source of EPA and DHA 
precursor. Whether it has a direct beneficial effect is unknown
Olive and canola oil The MUFA OA (C18:1n-9) OA has a neutral effect on n-3 PUFA metabolism and incorporation into 
tissues; therefore, it provides a useful ‘background’ dietary fat for 
maximizing n3 tissue content from dietary n3 PUFAs
Sunflower, peanut,  The n6 PUFA LA (C18:2n-6) Intake in modern Western diets is generally high and far in excess of 
soybean and cottonseed oil what is required to prevent deficiency. Dietary LA can decrease 
conversion of dietary ALA to tissue EPA and can decrease tissue levels 
of EPA and DHA. LA is a precursor of AA (C20:4n-6), which is a 
metabolic antagonist of EPA
AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MUFA, monounsaturated
fatty acid; OA, oleic acid; PUFA, polyunsaturated fatty acid.
Figure 1
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acknowledge that PGH2 and not PGE2 is the immediate
product of AA metabolism by COX, and that PGH2 is the
common precursor for many eicosanoids, including vaso-
active and platelet active TXA2 and prostacyclin (PGI2; Fig. 2).
For reasons explained by the enzymology of the individual
synthases, antithrombotic PGI2 is mainly COX-2 derived
whereas prothrombotic TXA2 is mainly COX-1 derived [12].
Thus, selective COX-2 inhibitors suppress prostacyclin
synthesis but not thromboxane synthesis [13,14], which is a
potential mechanism for the excess of adverse cardiovascular
events seen with use of the coxibs [15]. This outcome is not
observed with use of dietary EPA as fish oil.
Eicosanoids: 5-lipoxygenase pathway
In addition to its effects on COX metabolism, fish oil in anti-
inflammatory doses also inhibits AA metabolism by
5-lipoxygenase and thereby reduces production of the potent
chemotactic factor leukotriene B4 (Fig. 3) [16,17]. This effect,
attributable to EPA, is not seen with NSAIDs, which have no
inhibitory effect on the 5-lipoxygenase pathway.
Cytokines
Other inflammatory mediators whose production is inhibited by
fish oil are the cytokines tumour necrosis factor (TNF)-α and
interleukin-1β, which are involved not only in production of
inflammatory signs and symptoms but also in cartilage
degradation (Fig. 3) [18-21]. In contrast to its inhibition by fish
oil, TNF-α synthesis by monocytes is increased by NSAIDs [22].
Clinical evidence for the anti-inflammatory
effects of fish oil
Fish oil has been shown to reduce symptoms in RA in a dose-
dependent manner [8,23], relapse rates in Crohn’s disease
[24] and progression to renal failure in immunoglobulin A
nephropathy [25]. Fish oil improves control in systemic lupus
erythematosus [26] and has a preventive effect when given
prophylactically to mice genetically predisposed to lupus [27].
Dose–response relationships
Investigations across a variety of inflammatory diseases have
used doses of fish oil that provide daily intakes of LC n3
Available online http://arthritis-research.com/content/8/1/202
Figure 2
Metabolism of AA or EPA by COX. –, inhibition; AA, arachidonic acid; COX, cyclo-oxygenase; EPA, eicosapentaenoic acid; NSAID, nonsteroidal
anti-inflammatory drug; PG, prostaglandin; TX, thromboxane.
Figure 3
Effect of EPA on the production of eicosanoids and inflammatory cytokines. *Three different synthases (PGE, PGI, and TX synthase), each with
different enzyme kinetic characteristics. –, inhibition; AA, arachidonic acid; COX, cyclo-oxygenase; EPA, eicosapentaenoic acid; IL, interleukin; LT,
leukotriene; NSAID, nonsteroidal anti-inflammatory drug; PG, prostaglandin; TNF, tumour necrosis factor; TX, thromboxane.PUFAs that range from less than 1 g to more than 6 g [8].
Collectively, these studies indicate that the anti-inflammatory
dose of fish oil requires delivery of 2.7 g or more of LC n3
PUFAs daily, and that higher doses are also safe and
effective. A daily intake of 2.7 g EPA plus docosahexaenoic
acid (DHA) is provided by a daily dose of nine or more
standard fish oil capsules, which typically contain 30% LC n3
PUFAs w/w. People who self medicate with fish oil generally
take one or two capsules daily. This is insufficient for an anti-
inflammatory effect but it may provide cardiovascular benefit.
Delay of symptomatic benefits
The symptomatic benefit of fish oil in RA can be delayed
2–3 months [8]. Earlier improvement with higher doses
suggests a possible loading effect. It is important that
potential users understand that this delay exists.
Influence of background diet
Increased ingestion of n3 PUFAs from vegetable sources
yields modest changes in LC n3 PUFAs in most tissues
compared with fish oils taken in anti-inflammatory doses.
However, avoidance of n6 PUFAs in visible fats (i.e. spreads,
cooking oils, mayonnaise, nuts) can increase LC n3 PUFA
levels achieved with a given dose of fish oil [3]. Reduction in
n6 PUFA intake can be achieved simply by choosing options
that are rich in MUFAs, such as olive oil or canola oil based
products, or that are rich in n3 PUFAs, such as flaxseed oil or
fresh ground flaxseed. Patients should be advised to avoid
products labelled as containing polyunsaturated oils because
this generally means an n6-rich oil. Canola and olive oil based
products generally are so marked. The substitutes suggested
above are inexpensive and contain little undesirable saturated
fat. A suggested guide to background diet is given in Table 2.
Cost
Cost has been a major impediment to use of fish oil in anti-
inflammatory doses. At the time of the major trials of fish oil in
RA in the 1980s and 1990s, the cost for 1 g fish oil capsules
was typically 30 c per capsule. For 15 capsules of fish oil
daily (an average dose for RA trials showing benefit), the
annual cost at this price is about A$1650 per annum. For
most users this cost is prohibitive, and is particularly
discouraging when most other treatments are government
subsidized. The Pharmaceutical Benefits Scheme in Australia
makes subsidized drugs, irrespective of actual cost, available
to consumers at A$4.60 for Health Cardholders and
A$28.60 for others for a typical 1-month supply. Fish oil,
although available without prescription and with unrestricted
access, is thus far more expensive to users than even highly
expensive subsidized drugs. Recently, the cost of fish oil
capsules has fallen. Products are now available that provide
large numbers of capsules at an average cost as low as 10 c
per capsule. Although this has reduced the annual cost for an
anti-inflammatory dose to about A$550, the cost remains
almost twice what non-Health Cardholders pay for most
pharmaceutical products. The cost can be reduced
substantially by using bottled fish oil taken on juice, a 15 ml
daily dose of which costs about A$150 per annum. This
Arthritis Research & Therapy    Vol 8 No 1 Cleland et al.
Page 4 of 9
(page number not for citation purposes)
Table 2
Fatty acid information for food choices
Foods, ingredients Choices Fatty acids
Cooking oils, salad dressings and spreads Choose:
Canola oil products ALA (18-carbon n3 PUFA)
Olive oil products OA (MUFA)
Avoid:
Sunflower, cottonseed, peanut,  LA (18-carbon n-6 PUFA)
soybean oil products
Preprepared food such as frozen chips/fries Nutrient information on the packet will allow 
a choice of foods prepared in canola or olive oils
Fish Because fish oil is rich in long chain n3 fats,  EPA (20-carbon n3 PUFA) 
fatty fish (e.g. sardines, herrings) have higher  DHA (22-carbon n-3 PUFA)
n3 content than lean fish. However, all marine 
fish contain long chain n3 fats. Canned fish 
have n3 fat content also, but note that canned 
tuna has less fat (and therefore less n3 fat) 
than fresh tuna
Nuts and seeds Flaxseed (linseed) High in n3 PUFAs
Walnuts Some n3 PUFAs but also n6 PUFAs
Macadamia, almonds High in MUFA, low in n6 PUFAs
Peanuts, cashews, brazil and hazel nuts Some MUFA, but also n6 PUFAs
ALA, α-linolenic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; MUFA, monounsaturated fatty acid; OA, oleic
acid; PUFA, polyunsaturated fatty acid.makes fish oil somewhat less expensive than many standard
medications for non-Health Cardholders but more expensive
than the approximately A$55 per annum paid by Health
Cardholders per medication below the safety net.
Availability and merits of different fish oils
Oils derived from marine fish oil all contain LC n3 PUFAs.
Standard fish oil is extracted from fish bodies and typically
contains EPA 18% and DHA 12% w/w. Until recently, this
was available only in capsules, but now a bottled preparation
is available in Australia. Cod liver oil is widely available as
both bottled oil and in capsules. It contains approximately
10% EPA and 10% DHA, and so it is also a good source of
LC n3 PUFAs. However, at anti-inflammatory doses cod liver
oils, which are rich in the fat-soluble vitamins A and D, contain
more vitamin A than recommended intakes. Although the
amount does not cause symptoms of toxicity, similar doses
have been associated with reduced bone density and
increased risk for hip fracture in epidemiological studies [28].
This is not a problem with fish body oils, which contain very
little of these fat-soluble vitamins.
Technique for taking bottled fish oil
Fish oil has a taste and odour that most people find
unpleasant, and for this reason it has been largely distributed
within capsules. However, the taste of fish oil can be masked
partially with flavouring (e.g. citrus, peppermint). The taste
can be avoided more completely by taking fish oil on juice
using a method that avoids contact of fish oil with the lips
where the fish oil taste is experienced.
1. Pour 30–50 ml juice (e.g. orange, tomato, apple, etc.)
into two small ‘shot’ glasses.
2. Layer the desired dose of fish oil onto the juice in one
glass – do not stir.
3. Swallow the juice and fish oil with a single gulp, avoiding
contact with the lips (where the fish oil can be tasted).
4. Immediately sip the juice in the other glass slowly
through the lips. This will remove any oil from the lips.
5. Take the fish oil immediately before a solid meal and
without further fluid. This avoids floating of the oil on fluid
in the stomach and favours mixing of the fish oil with food
and passage from the stomach into the intestine. If reflux
(repeating taste) becomes a problem, then split the dose
before morning and evening meals. Alternatively, take the
dose then lie on the left side for at least 15 min. In this
position the oil floats into the passage from the stomach
to the small intestine.
6. Fish oil (obtained from the body of the fish) is preferable
to cod liver oil, which can deliver undesirable amounts of
vitamin A at anti-inflammatory doses.
Avoidance of ‘repeating’ taste
The repeating taste of fish oil arises from its low specific
gravity, which is less than that of water. Thus, fish oil will float
on free fluid with the stomach, in the same way that it floats
on juice within a glass. Thus, when an eructation occurs to
vent the stomach of swallowed gas, fish oil at the gas–fluid
interface in the stomach may be partly regurgitated and
tasted. This experience can be minimized by avoiding
unnecessary fluids at the time of ingestion of fish oil, avoiding
aerated drinks and by taking fish oil immediately before a meal.
The latter strategy allows fish oil to mix with food, with which it
exits from the stomach into the small bowel. These measures
are generally effective in avoiding a ‘repeating’ fish oil taste. In
cases where a problem still exists, passage of fish oil into the
duodenum can be facilitated by lying in the left lateral
decubitus position; this allows the oil to float into the
duodenum, which is above the stomach in this position [29].
Some may have a lesser problem with capsules than fish oil on
juice but these can also be problematic because fish oil is
released from capsules within the stomach. Some patients with
persistent oesophageal reflux may not be able to take fish oil.
The odour of fish oil can be minimized by keeping fish oil
refrigerated once open and taking it quickly once the fish oil
on juice technique is mastered.
Effect of fish oil on body weight
Fish oil, like any fat, is rich in calories. However, most people
eat to satiety. In our Early Arthritis Clinic, a cohort of 33 RA
patients taking fish oil at the rate of 15 ml/day immediately
before or during a meal did not increase their mean weight over
1 year; there was a nonsignificant mean change of –0.4 kg
from baseline to 1 year. Metabolic studies suggest the LC n3
PUFAs present in fish oil can reduce adipocyte numbers and
the contribution of adipose tissue to body mass [30].
Use in pregnancy
Because most anti-inflammatory drugs can have adverse
effects on the foetus, they are generally withdrawn during
pregnancy and lactation. Early observations in patients with
active RA suggest a tendency toward lessening disease
activity in pregnancy. This improvement presumably results
from release of immunosuppressive factors that are generated
during pregnancy, putatively to prevent immunological rejection
of the foetus. In the modern era, in which RA is generally well
suppressed by medications, withdrawal of medication in
anticipation of and during pregnancy often results in increased
disease activity. It is therefore appropriate to consider the
safety of fish oil in pregnancy, either as an alternative or as one
component of established treatment that may be continued.
LC n3 PUFAs are strongly represented among neural lipids.
Neural tissue forms a disproportionately high proportion of
body weight in foetuses and, relative to adults, neural
development is particularly active in utero and during infancy.
n3 PUFAs provided through placental transfer to the foetus
or in breast milk, which is rich in LC n3 PUFAs, supports
requirements for this development. As a result the possibility
of depletion of maternal LC n3 PUFA stores exists. There is a
dramatic fall in maternal plasma DHA in the immediate
postpartum period, which is a time when relapse or onset of
Available online http://arthritis-research.com/content/8/1/202
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[31,32]. Although there are no studies comparing women
receiving fish oil with control women, hypothetically n3
depletion could play a role.
Populations with high maternal n3 intakes have higher infant
birth weight [33]. In premature infants, breast feeding and n3-
enriched infant formula have been associated with
accelerated neural development compared with their counter-
parts given n3 PUFA poor formula [34]. Although there are
no studies into the anti-inflammatory effects of fish oil in
pregnancy, symptomatic benefit in RA studies, in which
women typically outnumber men, is well established. Thus,
there is a rationale for use of fish oil in pregnant and lactating
women with RA, and there is no evidence of harm at
supplementation levels of at least 2.7 g/day of LC n-3 PUFAs
[32]. This dose is provided by 10 ml bottled fish oil (not cod
liver oil) or the equivalent 9 or 10 standard fish capsules per
day, and is in the range of doses shown to have anti-
inflammatory effect. There is no evidence higher doses would
be toxic to mother or foetus, but a conservative approach
would be to limit the fish oil dose to this level. In pregnancy
oesophageal reflux is common. Accordingly, attention to time
of dosing (preferably morning or middle of the day and
immediately before or during the early phase of a low fat
meal) and reduced amount of juice with the dose and its
chaser may be especially important.
Drug–fish oil interactions
There are several potentially useful drug–fish oil interactions
relevant to the management of arthritis.
Fish oil and nonsteroidal anti-inflammatory drugs
As discussed under biochemical rationale (see above), fish
oils contain the natural COX inhibitor EPA, which inhibits
both COX-1 and COX-2 activity. The different effects of EPA
and NSAIDs on synthesis of downstream products are
consistent with the known cardioprotective effect of fish oil
and increased cardiovascular risk associated with NSAIDs
(especially those that are COX-2 selective). Fish oils have
been shown to reduce discretionary NSAID use for analgesia
by about 50%. Fish oil has not been associated with gastric
irritancy. NSAIDs tend to cause a moderate increase in
systemic blood pressure, whereas fish oil reduces blood
pressure by a similar amount [35,36].
Fish oil and cyclosporin
The most common dose-limiting effects of cyclosporin are
hypertension and impaired renal function. These effects
appear to be in part thromboxane mediated [37]. Fish oil
inhibits TXA2 production and reduces both the hypertensive
and nephrotoxic effects of cyclosporin [38].
Fish oil and tumour necrosis factor blockade
Fish oil in anti-inflammatory doses inhibits TNF and inter-
leukin-1 synthesis by peripheral blood mononuclear cells
stimulated ex vivo [18,20,21]. A rationale therefore exists for
concomitant use of fish oil and TNF blockers. To date, this
combination has not been evaluated in formal clinical trials.
Fish oil and methotrexate
Gastrointestinal toxicity is common with methotrexate therapy
and is often dose limiting. Animal studies show that LC n3
PUFAs reduce loss of appetite, weight loss and gastro-
intestinal damage associated with methotrexate therapy [39].
Intolerance to fish oil
Intolerance to fish oil is not unusual and occurs in about 15%
of patients offered this treatment. Unwanted effects include
repeating taste, retrosternal burning, diarrhoea, aversion to
odour and taste, headache and failure to mask taste. Some
patients are unable to accept the idea of taking fish oil.
Serious unwanted effects have not been reported.
Continuation rates
In a long-term study of fish oil in RA (>3 years), the
continuation rate for fish oil was about 80% (unpublished
data). This compared favourably with the continuation rates
for each of the first-line disease-modifying antirheumatic
drugs used concurrently, namely methotrexate, sulpha-
salazine and hydroxychloroquine.
Safety
Although fish oil has not been associated with any serious
acute treatment related syndromes, its long-term use raises
several theoretical and practical concerns. These are
discussed below.
Safe limits of long chain n3 polyunsaturated fatty acid
ingestion
A dose of 3 g/day EPA plus DHA has been assessed as safe
for general consumption [40]. Greenland Inuits consuming
their aboriginal diet of sea mammals, sea birds and fish ingest
7 g/day LC n3 PUFAs [41]. These Inuits appear to have a
bleeding tendency, which may contribute to an observed
increase in apoplexy (cerebral haemorrhage) [42]. The very
high consumption of LC n3 PUFAs in this population occurs
within the context of a low n6 PUFA intake. The equivalence
of AA and EPA in Inuit platelet cell membranes (AA:EPA ratio
1:1) was not reached closely by Australian patients taking
4.5 g fish oil for RA (AA:EPA ratio 4:1) for more than 3 years,
although this ratio is substantially different from that in healthy
Australian control individuals not taking fish oil and
consuming an ordinary diet (AA:EPA ratio 40:1) [19,43]. The
Inuits have a very low frequency of myocardial infarction
(relative risk 0.075 compared with Danish control individuals),
which appears to be due in major part to dietary PUFAs [42].
They also have a low frequency of inflammatory diseases. For
patients with a chronic inflammatory disease such as RA,
which is associated with high cardiovascular risk [44], the
reduced cardiovascular risk with and anti-inflammatory effect
of fish oil is likely to yield an overall long-term advantage. The
Arthritis Research & Therapy    Vol 8 No 1 Cleland et al.
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is unknown. However, the inhibitory effect of anti-
inflammatory doses of fish oil on TNF and interleukin-1
synthesis provides the potential basis for a favourable long-
term effect on disease progression.
Bleeding tendency
Within the Western context, fish oil supplements have not been
associated with an increased bleeding tendency, even in
patients taking aspirin or warfarin for antithrombotic effect [45].
Lipid peroxidation
Concerns have been raised that fish oils, which contain highly
unsaturated n3 PUFAs, lead to accumulation of lipid
peroxides in vessels, which may increase cardiovascular risk.
There is no convincing evidence that such a pathological
accumulation is aggravated by fish oil. In any case, the overall
effect of fish oil is to reduce rather than increase cardio-
vascular risk [46].
Mercury
Methylmercury is an industrial contaminant that accumulates
in long-lived fish (e.g. swordfish, marlin, sea perch, shark).
Methylmercury is a neurotoxin that impairs neural develop-
ment, especially in the foetus and infants. Fish consumption
has been associated with increased blood and urine mercury
[47,48]. Properly processed fish oils contain very little
mercury. Increased blood and urine mercury was not seen in
a group of patients taking fish oil at 15 ml/day (4.5 g EPA
plus DHA per day) for more than 3 years (unpublished data).
Halogenated biphenyls
Chlorinated biphenyls (PCBs) are byproducts of industrial
synthesis of organic chemicals.  They are structurally related
to dioxins and are potentially toxic. Industrial processes that
produce PCBs have been outlawed because these
compounds are poorly biodegradable and they have been
found to accumulate in the land and marine food chains. Of
continuing concern are polybrominated biphenyl (PBB) fire
retardants, the production of which is still allowed. With
regard to their poor biodegradability, accumulation and toxic
potential, PBBs are similar to PCBs. Although the level of
environmental contamination of PBBs is substantially less
than that of PCB, their continued production means
increasing accumulation, and alternatives are being sought.
Halogenated biphenyls can be removed from fish oils by
molecular distillation and should be present at low levels in
good quality products [49].
Possible preventive effects against
inflammatory disease
Epidemiological studies show lower frequencies of RA in
populations that consume higher amounts of LC n3 fats [50].
However, these differences could be due to incidental
unidentified environmental or genetic factors. With regard to
the latter, the RA disease susceptibility epitope is not
responsible because the Japanese and Inuits, who have high
fish intakes and low prevalence of RA, both have relatively
high frequencies of DR4 alleles, which confer disease
susceptibility [51,52].
Control of disease activity in systemic lupus erythematosus
can be improved with fish oil, as shown in clinical studies and
in murine lupus. In the latter, preventive regimens, begun at
an age before the disease emerges, can have a strong
preventive effect [27]. Considering the safety of fish oil and
the increased cardiovascular risk seen in lupus, fish oil seems
a reasonable option for treatment of ‘minimal lupus’, which is
defined as the presence of arthralgia and a strongly positive
antinuclear antibody. (Fish oil might reasonably be combined
with hydroxychloroquine in this setting, and has the advan-
tage of freedom from serious unwanted effects.)
Range of therapeutic applications of fish oil
As discussed under clinical evidence for the anti-inflammatory
effects of fish oil (see above), fish oil has been found to have
therapeutic effects in several inflammatory diseases. Fish oil
has been studied most intensively in RA, where there is
level 1 evidence for symptomatic improvement [8]. There is
level 2 evidence for a strong preventive effect against relapse
in Crohn’s disease and against progression of renal failure in
immunoglobulin A nephropathy [24,25]. Some types of
psoriasis (guttate, pustular) have been shown to improve with
oral fish oil given in anti-inflammatory doses [53-55]. Fish oil
improves control in systemic lupus erythematosus [26,56]. In
addition to this catalogue of disorders, which share an
autoimmune-based inflammation in their pathogenesis, there
is strong evidence for cardiovascular benefit with fish oil.
Cardiovascular benefit
Dietary fish and fish oil have been shown to reduce cardio-
vascular risk in epidemiological studies and in secondary
prevention trials after myocardial infarction. Perhaps the most
potent effect of dietary LC n3 PUFAs is to stabilize the
myocardial membrane, thereby reducing ventricular fibrillation
and sudden death.
The antiarrhythmic effect of LC n3 PUFAs has been demon-
strated in vitro in studies of cardiomyocytes challenged by
various stimuli [57]. Fish oil or purified n3 fatty acids reduced
the incidence of arrhythmias in animal models of
ischaemically induced ventricular fibrillation [58,59]. These
findings correlate with the striking reduction in cardiac
mortality and, in particular, sudden cardiac death seen with
fish oil and diets rich in n3 PUFAs from vegetable sources
after myocardial infarction [46,60,61]. This effect on sudden
death can be seen with under 1 g/day LC n3 PUFAs (i.e. less
than the anti-inflammatory dose) [46].
At anti-inflammatory doses of fish oil other cardiovascular
benefits can be seen. These include improved blood pressure
control, reduced fasting triglycerides, more rapid clearance of
Available online http://arthritis-research.com/content/8/1/202
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(page number not for citation purposes)chylomicrons, increased high-density lipoprotein cholesterol,
reduced total cholesterol to high-density lipoprotein choles-
terol ratio, reduced atheroma (in experimental animals), and
improved arterial compliance and flow mediated dilation (for
review, see Din and coworkers [62]).
Importantly, a meta-analysis of large, long-term randomized
controlled trials of anti-lipidaemia agents [63] showed that
strategies that increase LC n3 PUFA intake reduce
annualized death rates to an extent as least as great as that
with statins, which is the only other intervention to have
significant benefit. That fish oil is not used more widely to
manage cardiovascular risk appears to reflect more the
influence of pharmaceutical product marketing on the
practice of ‘evidence-based medicine’ than the merits of fish
oil relative to those of commonly used proprietary agents.
Conclusion
In a medical environment in which messages molded by
pharmaceutical interests stress the ‘need’ for NSAIDs,
prescribers should consider the NSAID-sparing effects, the
lack of serious side effects and the positive health benefits of
fish oil. Importantly, recipients should be informed that there
is a ‘mainstream’ evidence base for such a recommendation,
thereby distinguishing dietary n3 fats from many other
nonprescription items that are grouped loosely as
‘complementary medicines’.
Although modest increases in intake of n3 LC PUFAs can
reduce cardiovascular risk, relatively large doses (≥2.7 g/day
EPA plus DHA) are required for anti-inflammatory effects.
These doses can be taken efficiently and economically as
liquid fish oil on juice. Recipients should be informed that
there are multiple strategies for increasing n3 intake, and
therefore, no matter what are their usual dietary preferences,
there should be an acceptable approach for most individuals.
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